1. 1601 The multicenter, prospective observational study of the 5-HT3 receptor antagonist and dexamethasone as prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in moderately emetic chemotherapy (MEC) for solid tumors. (September 2015) Authors: Sugita, K.; Matsui, R.; Suzuki, K.; Takiguchi, T.; Nishio, M.; Koike, T.; Hayashi, T.; Seto, T.; Kogure, Y.; Nogami, N.; Fujiwara, K.; Kaneda, H.; Harada, T.; Shimizu, S.; Kimura, M.; Kenmotsu, H.; Shimokawa, M.; Goto, K. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S238 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3072 Phase 2: Docetaxel with or without ramucirumab as therapy for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations after prior EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy. (September 2015) Authors: Kasahara, K.; Kiura, K.; Nogami, N.; Takayama, K.; Takiguchi, Y.; Hirashima, T.; Aoe, K.; Hayashi, H.; Saka, H.; Takahashi, K.; Imamura, F.; Oizumi, S.; Inoue, A.; Satouchi, M.; Tatsumi, M.; Nakamura, T.; Enatsu, S.; Tamura, T.; Nakagawa, K. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S620 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 521 Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC). (September 2015) Authors: Sakai, H.; Nishio, M.; Hida, T.; Nakagawa, K.; Nogami, N.; Atagi, S.; Takahashi, T.; Nokihara, H.; Saka, H.; Takenoyama, M.; Fujita, S.; Tanaka, H.; Takeda, K.; Satouchi, M.; Isobe, H.; Maemondo, M.; Goto, K.; Hirashima, T.; Minato, K.; Tamura, T. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗